Last updated: 2026-10-12 21:27:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Damora Therapeutics, Inc. (DMRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $20,25, with a market capitalisation of $1,30B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16,50 to $34,89. This page covers its latest market performance, valuation, price trends and company information.
$1,30B | |
$20,93 | |
$34,89 | |
$16,50 | |
$21,08 | |
231,32K | |
537,01K | |
-- | |
$34,89 | |
$16,50 | |
-- | |
-- |
Damora Therapeutics, Inc. (DMRA) is trading at $20,25 in after-hours trading as of 2026-10-12 20:13:00, down 3,96% ($0,83) from the regular-session close of $21,08.
After-hours trading shows how investors are pricing DMRA after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Damora Therapeutics, Inc. (DMRA) moved from $20,23 to $20,25, representing a gain of 0,07% ($0,02).
The stock traded between $18,20 and $21,95 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 567,79 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20,4%
DMRA is currently trading at $20,25, placing it 20,4% of the way from its 52-week low of $16,50 to its 52-week high of $34,89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Damora Therapeutics, Inc. (DMRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.